CTRI/2013/12/004211进行中（未招募）3 期
A Randomized, Double-Blind, Active-Controlled,Phase 3 Study to Evaluate the Efficacy and Safety ofBaricitinib (LY3009104) in Patients with Moderately toSeverely Active Rheumatoid Arthritis Who Have HadLimited or No Treatment with Disease-ModifyingAntirheumatic Drugs
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 入组人数
- 550
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Have a diagnosis of adult-onset rheumatoid arthritis (RA) as defined by American College of Rheumatology or European League Against Rheumatism (ACR or EULAR) 2010 Criteria for the Classification of RA
- •-Have documented history of positive rheumatoid factor and/or cyclic citrullinated peptide (CCP) antibody test
- •-Have moderately to severely active RA defined as the presence of at least 6 per 68 tender joints and at least 6 per 66 swollen joints
- •-Have a C-reactive protein (CRP) or high-sensitivity C-reactive protein (hsCRP) measurement greater than equal to 1.2 times the upper limit of normal (ULN)
- •-Have had limited or no treatment with methotrexate (MTX)
排除标准
- •-Have received conventional disease-modifying antirheumatic drugs (DMARDs) other than MTX (eg, gold salts,cyclosporine, leflunomide, azathioprine, hydroxychloroquine,sulfasalazine or any other immunosuppressives)
- •-Are currently receiving corticosteroids at doses greater than 10 mg per day of prednisone (or equivalent) or have been receiving an unstable dosing regimen of corticosteroids within two weeks of study entry or within 6 weeks of planned randomization
- •-Have started treatment with non-steroidal anti-inflammatory drugs (NSAIDs) or have been receiving an unstable dosing regimen of NSAIDs within 2 weeks of study entry or within 6 weeks of planned randomization
- •-Have started a new physiotherapy treatment for RA in the 2 weeks prior to study entry
- •-Have ever received any biologic DMARD
- •-Have received interferon therapy within 4 weeks prior to study entry or are anticipated to require interferon therapy during the study
- •Have received any parenteral corticosteroid administered by intramuscular or intravenous (IV) injection within 2 weeks prior to study entry or within 6 weeks prior to planned randomization or are anticipated to require a parenteral injection of corticosteroids during the study
- •-Have had 3 or more joints injected with intraarticular corticosteroids or hyaluronic acid within 2 weeks prior to study entry or within 6 weeks prior to planned randomization
- •-Have active fibromyalgia that, in the investigators opinion, would make it difficult to appropriately assess RA activity for the purposes of this study
- •-Have a diagnosis of any systemic inflammatory condition other than RA, such as, but not limited to, juvenile chronic arthritis, spondyloarthropathy, Crohns disease, ulcerative colitis, psoriatic arthritis, active vasculitis, or gout (Participants with secondary Sjogrens syndrome are not excluded)
- •-Have a diagnosis of Feltys syndrome
- •-Have had any major surgery within 8 weeks of study entry or will require major surgery during the study that, in the opinion of the investigator in consultation with Lilly or its designee, would pose an unacceptable risk to the participant
- •-Have experienced any of the following within 12 weeks of study entry, myocardial infarction, unstable ischemic heart disease, stroke, or New York Heart Association Stage IV heart failure
- •-Have a history or presence of cardiovascular, respiratory, hepatic, gastrointestinal, endocrine, hematological, neurological, or neuropsychiatric disorders or any other serious and or unstable illness that, in the opinion of the investigator, could constitute a risk when taking investigational product or could interfere with the interpretation of data
- •-Are largely or wholly incapacitated permitting little or no self care, such as, being bedridden or confined to a wheelchair
- •-Have an estimated Glomerular Filtration Rate (eGFR) based on the most recent available serum creatinine using the Modification of Diet in Renal Disease (MDRD) method of less than 40 milliliter per minute per 1.73 m2 (mL/min/1.73 m2)
- •-Have a history of chronic liver disease with the most recent available aspartate aminotransferase (AST) or alanine aminotransferase (ALT) greater than 1.5 times the ULN or the most recent available total bilirubin greater than equal to 1.5 times the ULN
- •-Have a history of, lymphoproliferative disease, or have signs or symptoms suggestive of p
研究者
相似试验
已完成
1 期
A Phase I Clinical Study to assess the Safety and Tolerability of SII Typhoid Conjugate Vaccine (Bivalent) in Healthy AdultsCTRI/2022/06/043608Serum Institute of India Pvt Ltd60
已完成
3 期
A Randomized, Double-Blind, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of SAR236553/REGN727 over 24 weeks in Patients with Hypercholesterolemiahypercholesterolemiahypercholesterolemiehigh cholesterolNL-OMON36881Sanofi-aventis30
进行中（未招募）
1 期
Efficacy and Safety of SAR236553 (REGN727) Versus Ezetimibe in Patients with HypercholesterolemiaHypercholesterolaemiaMedDRA version: 16.1Level: PTClassification code 10020603Term: HypercholesterolaemiaSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2011-001424-38-BEsanofi-aventis Recherche & Développement182
进行中（未招募）
不适用
Efficacy and Safety of SAR236553 (REGN727) Versus Ezetimibe in Patients with HypercholesterolemiaEUCTR2011-001424-38-NLsanofi-aventis Recherche & Développement182
进行中（未招募）
不适用
Efficacy and Safety of SAR236553 (REGN727) Versus Ezetimibe in Patients with HypercholesterolemiaEUCTR2011-001424-38-FIsanofi-aventis Recherche & Développement182